UroGPO members will gain access to Gemini’s Atmos air-charged urodynamics catheter line through the deal. Atmos is made from a flexible polyurethane material that softens when inside the body to alleviate discomfort by easily bending with the movements of a patient. Product tests have shown that Atmos catheters deliver reliable and accurate results and match the diagnostic standards set by other brands and ICS guidelines, according to the company . “We are honored to have been awarded this agreement with UroGPO. We know that practices are having their margins squeezed, and a large part of that is how much the average price of consumables has increased. Catheter pricing has nearly doubled over the last three years. We are giving physicians a new option for urodynamics testing that delivers reliable results and premium comfort at a responsible price,” Brian Hersh, Gemini’s general manager, said in a news release . Specialty Network’s portfolio includes group purchasing organizations specializing in gastroenterology, urology and rheumatology. It represents over 11,000 providers and independent physician practices.

Gemini Medical partners with UroGPO for improved access to air-charged urodynamic catheters

News provided by
Share this article
Share this article
BIRMINGHAM, Ala., Nov. 16, 2022 /PRNewswire/ -- Streamline Scientific  announced a new partnership today with UroGPO , a pairing that will support urologists and their in-house PCR testing labs with the goals of improving clinical insights, enhancing patient experience, and optimizing reimbursement for privately-owned urology practices. "This partnership is a seamless extension of our mission at Streamline Scientific," Streamline Scientific's CEO Ted Kramm said. "We look forward to supporting UroGPO's community-based, private urology practices to establish and support physician office labs, helping these practices remain independent while benefiting from leading PCR technologies that have the ability to enhance patient care." UroGPO is a group purchasing organization that provides purchasing and educational services to urology professionals, connecting them with top manufacturers and service organizations to improve operations, enhance revenue, and reduce costs in their practice. Members of the organization also have the opportunity to network with other members, which includes urology group practice leaders, administrators, medical directors, CEOs, and more. The experts at Streamline Scientific provide end-to-end consultation services for physician practices and reference labs across the country as they implement in-house PCR labs. The organization also has a CLIA-certified reference lab in Alabama that specializes in delivering molecular and toxicology testing results in under 24 hours. PCR testing is an advanced molecular diagnostic technology  that can produce results in under two hours, as opposed to traditional testing methods that can take around two to three days to yield results. Expedited results can lead to better-informed treatment decisions and support antibiotic stewardship. The World Health Organization has identified antibiotic resistance as one of the biggest threats  to global health. This is especially important in urology during the treatment of UTIs—a common infection among pregnant women that can lead to serious risks if undiagnosed or mistreated. The proven efficiency and reliability of PCR testing can help urologists to pinpoint the appropriate course of antibiotic treatment more quickly than with other methods. About Streamline Scientific
Streamline Scientific is a team of medical doctors and scientists working to simplify the delivery of molecular technologies. In addition to helping set up over 200 labs in 43 states, Streamline Scientific maintains its own CLIA-certified reference labs in Alabama. As experts in PCR in-house lab setup and operation, their consulting services provide an end-to-end implementation solution for physician practices and reference labs nationwide. For more information, visit www.streamlinesci.com/
Contact:

08:00 ET
Streamline Scientific and UroGPO Form Partnership to Offer Physician Office Lab Implementation and Consulting Services ...

News provided by
Share this article
Share this article
PLAINVIEW, N.Y. and CLEVELAND, Sept. 7, 2022 /PRNewswire/ -- Acupath Labs and UroGPO announced in April a partnership to make URO17® available to the UroGPO membership nationwide. URO17® is a non-invasive, cost-effective urine-based biomarker used in diagnosis and management of bladder cancer, the 6th most common form of cancer in the US. Available as a Laboratory Developed Test (LDT) in the United States, Acupath was the first lab worldwide to offer URO17® in July 2019 and has performed over 20,000 tests since that time. UroGPO will offer discounted reagents and information for the URO17® test to the members of their Group Purchasing Organization. Each year over 85,000 new cases of bladder cancer are diagnosed, while many more patients are subjected to unnecessary and invasive procedures to address common symptoms such as hematuria, or blood in the urine. With a high sensitivity and negative predictive value (NPV), URO17 can provide invaluable information and help clinicians better risk stratify patients, identifying those that require additional and often invasive follow up treatments, and those that do not. Further, for urology practices with Physician Office Labs (POL's) or commercial / hospital pathology labs, URO17 represents an opportunity to generate a significant new and clinically relevant revenue stream. Acupath Labs and the UroGPO network are excited to formally make URO17® available to urology practices nationwide. "Acupath has worked closely with UroGPO for the last several years and we are excited to formally make URO17® available to urology practices nationwide through the UroGPO network. In addition to the compelling clinical utility, our clients appreciative how URO17 can be seamlessly integrated into their practices' workflow and in office pathology labs, often with no additional investment." says John Cucci, Chief Sales Officer of Acupath Laboratories, Inc. 
"As we expand our solutions around bladder cancer care, UroGPO has been pleased with the addition of URO17® to our membership offerings. Acupath partners with members as a consultant for all things implementation and optimization, which has proven to be a unique point of value in this offering. This partnership has strengthened our commitment to improving patient outcomes," says Palmer DePetro, Sr. Director, Contracting at Specialty Networks. About Acupath Laboratories, Inc. Founded in 1998 and based in Plainview, New York, Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women's Health, Otolaryngology, Podiatry, and Hematology / Oncology. Acupath offers an extensive test menu on both a global and TC/PC basis, processes over 500,000 specimens annually, and is the first lab worldwide to offer URO17™, an innovative bladder cancer biomarker, designated as a "Breakthrough Device" by the FDA in 2019. About UroGPO
UroGPO, a Specialty Networks Company, is the first and largest urology-specific Group Purchasing Organization (GPO) in the United States, comprised of more than 700 of the largest, most progressive independent urology practices in the country. Our membership includes more than 7,500 urology providers, including 4,000 practicing urologists in 3,200 locations spanning 49 states. UroGPO is committed to helping urology groups remain independent by providing them with pre-negotiated purchasing contracts, development of new revenue streams such as In-Office Dispensing of Oral therapeutics, Clinical Guideline Development, and other resources in all areas of urology. The goals of UroGPO are to build stronger patient relationships by improving patient care, make significant positive impacts on in-practice operational efficiencies and streamline operational costs. About Specialty Networks
Specialty Networks brings together the functional expertise of UroGPO, GastroGPO, PPS Analytics, and SN Research to deliver innovative and meaningful solutions for independent specialty providers. Specialty Networks serves a highly specialized member network of 765+ physician group practices consisting of over 7,700 providers in urology and gastroenterology. Specialty Networks' mission is to help create clinical, economic, and operational value for our members leading to a positive patient impact. Contact:

Acupath Laboratories Inc. and UroGPO Announce a Partnership to Offer the URO17® Bladder Cancer Biomarker in the United States

News provided by
Share this article
Share this article
SAN JOSE, Calif. and CLEVELAND, May 27, 2022 /PRNewswire/ -- KDx Diagnostics and UroGPO announced today the partnership to provide the URO17® test (Research Use Only in the US) for the detection of bladder cancer. URO17® is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer and to improve patient diagnosis. This is also likely to improve the treatment path as URO17® is also now available as a Laboratory Developed Test (LDT) in the United States. UroGPO will offer reagents and information for the URO17® test to the members of their Group Purchasing Organization. With over 85,000 new cases of bladder cancer in the United States every year the most common symptom of bladder cancer is hematuria, or blood in the urine, and patients with hematuria need to be subjected to invasive cystoscopic procedures even though a large majority of patients with micro-hematuria will not have bladder cancer. The URO17® test, and its high sensitivity and NPV for bladder cancer, will assist in ruling these patients out for unnecessary cystoscopy and its invasive procedure and in turn reduce the work-up. KDx Diagnostics Inc. and UroGPO Announce a Partnership to Offer the URO17® NON-INVASIVE Urine Test for Bladder Cancer
"We are very excited to partner with UroGPO, the premier urology network and group purchasing organization in the US, to make our URO17® test and information available to their network of clinical laboratories. Through UroGPO, the urology laboratories will have direct access to ordering with a special in-network pricing which will facilitate the availability of URO17® to the urologists," says Sholeh Jahanfard, President of KDx Diagnostics Inc.
"UroGPO is happy to present this new partnership to our membership. The URO17® test adds efficiency and precision to the care of patients with bladder cancer. KDx has taken steps to remove barriers of access for both physicians and patients which will ultimately benefit patient outcomes, improve quality of life, and even mortality," says Palmer DePetro, Sr. Director, Contracting at Specialty Networks. About KDx Diagnostics Inc. Founded in 2017, KDx is focused on developing non-invasive cancer tests to improve early detection and therapy decisions in cancer. The URO17® bladder cancer test developed by KDx may prove to be the most sensitive and specific for bladder cancer developed to date. KDx plans to develop tests based on the same biomarker for other platforms and sample types and expand its product line into other cancer diagnostic tests. URO17® is available as LDT in the U.S.
About UroGPO
UroGPO, a Specialty Networks Company, is the first and largest urology-specific Group Purchasing Organization (GPO) in the United States, comprised of more than 700 of the largest, most progressive independent urology practices in the country. Our membership includes more than 7,500 urology providers, including 4,000 practicing urologists in 3,200 locations spanning 49 states. UroGPO is committed to helping urology groups remain independent by providing them with pre-negotiated purchasing contracts, development of new revenue streams such as In-Office Dispensing of Oral therapeutics, Clinical Guideline Development, and other resources in all areas of urology. The goals of UroGPO are to build stronger patient relationships by improving patient care, make significant positive impacts on in-practice operational efficiencies and streamline operational costs. About Specialty Networks
Specialty Networks brings together the functional expertise of UroGPO, GastroGPO, PPS Analytics, and SN Research to deliver innovative and meaningful solutions for independent specialty providers. Specialty Networks serves a highly specialized member network of 765+ physician group practices consisting of over 7,700 providers in urology and gastroenterology. Specialty Networks' mission is to help create clinical, economic, and operational value for our members leading to a positive patient impact. Contact:

KDx Diagnostics Inc. and UroGPO Announce a Partnership to Offer the URO17® NON-INVASIVE Urine Test for Bladder Cancer in the United States

Arkivfoto: Liselotte Sabroe/Ritzau Scanpix
09. sep 2020 KL.13:57
Medicoselskabet Ambu har indgået en aftale med indkøbsorganisationen UroGPO - den største amerikanske indkøbsorganisation på det private urologimarked.Aftalen går på engangscystoskopet Ascope 4 Cy...

Ambu lander kontrakt med stor amerikansk indkøbsorganisation

Acupath Laboratories provides anatomic pathology services across various medical specialties. The company offers diagnostic tests, including FISH testing for cancer detection, analysis of pathology specimens, and PCR testing for infections. Acupath serves the healthcare sector, providing services to physician offices, hospitals, and laboratories. It was founded in 1998 and is based in Plainview, New York.

Acupath Laboratories

PLAINVIEW , N.Y. and CLEVELAND , Sept. 7 , 2022 / PRNewswire / -- Acupath Labs and UroGPO announced in April a partnership to make URO17 ® available to the UroGPO membership nationwide .

UroViu provides single-use endoscopy solutions within the medical devices industry. The company offers a portable endoscopy platform and a range of cystoscopes and hysteroscopes aimed at workflow efficiency, procedure time reduction, and cross-contamination prevention in medical settings. UroViu's products are utilized in urology, urogynecology, and gynecology sectors. It was founded in 2016 and is based in Los Altos, California.

UroViu

KDx Diagnostics is a developer of diagnostic tests focused on early detection and management of cancer within the healthcare sector. The company offers the URO17 bladder cancer diagnostic test, a urine test designed to identify the presence of bladder cancer. KDx Diagnostics serves the healthcare industry with a focus on diagnostic testing and monitoring. It was founded in 2016 and is based in Campbell, California.

KDx Diagnostics

Q BioMed is a biomedical acceleration and development company.

Q BioMed

Ambu is a company that develops medical devices and solutions within the healthcare sector, particularly in endoscopy, patient monitoring, and emergency care. The company offers a range of single-use endoscopy products, including bronchoscopes, gastroscopes, and cystoscopes. Ambu's products are used in various medical specialties such as pulmonology, gastroenterology, urology, and emergency medicine. It is based in Columbia, Maryland.

Ambu

Acq - Fin

UroGPO is a healthcare company focused on creating clinical and economic value for independent specialty providers in the fields of urology, gastroenterology, and rheumatology. The company offers a range of services including group purchasing, population health management, clinical and business intelligence, and provider education and training. UroGPO primarily serves the healthcare industry, catering to specialty physician practices and groups. It is based in Rocky River, Ohio.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
2/27/2018	Acq - Fin		Nautic Partners	$XXM	0 FY undefined	1
9/23/2015	Unattributed	$XXM	Subscribe to see more	$XXM	0 FY undefined	10

Date	2/27/2018	9/23/2015
Round	Acq - Fin	Unattributed
Amount		$XXM
Investors	Nautic Partners	Subscribe to see more
Valuation	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined
Sources	1	10

First funding	2/27/2018
Last Funding	2/27/2018
Investor	Nautic Partners
Rounds	1 Acq - Fin
Board Seats
Type	Private Equity
Location	Rhode Island

How VCs Use CB Insights

Professional Services

Platform Overview

UroGPO

Total Raised

Investors Count

Funding, Valuation & Revenue

UroGPO Investors